← IRONWOOD PHARMACEUTICALS INC (IRWD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
IRONWOOD PHARMACEUTICALS INC (IRWD)
Pharmaceutical Preparations · market cap $717M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
12
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Ironwood Pharmaceuticals (IRWD) is a specialty pharma company with 253 employees and a $634M market cap, trading at ~$3.85/share. Its lead asset IW-3718 is in Phase 3 for refractory GERD, alongside a broader GI-focused pipeline including linaclotide (Phase 3, IBS-C) and several Phase 2 programs. Revenue has declined meaningfully from $443M in 2023 to $296M in 2025, with the company generating a slim $24M net profit in 2025 after a $1B loss in 2023.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IW-3718 | Phase 3 | Gastroesophageal Reflux Disease (GERD) |
| IW-6118 | Phase 2 | Healthy |
| Linaclotide Acetate | Phase 2 | Irritable Bowel Syndrome With Constipation |
| PPI | Phase 2 | Gastroesophageal Reflux Disease |
| MD-7246 | Phase 2 | Irritable Bowel Syndrome With Diarrhea (IBS-D) |
| Linaclotide | Phase 3 | Irritable Bowel Syndrome With Constipation |
| MD-0727 | Phase 2 | Hypercholesterolemia |
| MD-1100 Acetate | Phase 2 | Constipation |
| IW-9179 | Phase 2 | Diabetic Gastroparesis |
| Linaclotide 145 micrograms | Phase 3 | Opioid-Induced Constipation |
| Linaclotide 290 micrograms | Phase 3 | Irritable Bowel Syndrome Characterized by Constipation |
| LIN Dose A | Phase 2 | Functional Constipation in Children Ages 6-17 Years |
Price & technical context
3-month
-16.9%
6-month
+2.8%
12-month
+149.3%
52-wk range
$1.43–$5.39
vs 50-day MA
-12.5%
vs 200-day MA
-9.0%
Realized vol
89.2%
Max drawdown
-88.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IRWD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 12 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.